晚期胰腺导管腺癌常见临床参数的预后价值：一项为期十年的大型多中心队列研究

Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years.

作者信息

Zhang Chenyue, Dong Shu, Wang Lei, Yu Songlin, Zheng Yuwei, Geng Yanyan, Shen Xiaoheng, Ying Haifeng, Guo Yuanbiao, Yu Jinming, Deng Qinglong, Meng Zhiqiang, Li Zhaoshen, Chen Hao, Shen Yehua, Chen Qiwen

机构信息

Department of Integrative Oncology, Fudan University Shanghai Cancer Center; and Department of Oncology, Shanghai Medical College, Fudan University; Shanghai, 200032, China.

Digestive Endoscopy Center, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.

出版信息

Discov Med. 2018 Mar;25(137):91-98.

PMID:29641971

Abstract

OBJECTIVE

We conducted a multicenter cohort study to investigate the prognostic value of some commonly-used laboratory indices in advanced pancreatic ductal adenocarcinoma (PDAC).

METHODS

A multicenter cohort study was conducted from 2004 to 2013. The associations between laboratory indices and prognosis of advanced PDAC were examined.

RESULTS

This cohort consisted of 553 females (36.2%) and 973 males (63.8%). Patients at cancer stage III and IV were 595 (39.0%) and 931 (61.0%), respectively. The median survival of stage III patients was 9.0 months, with 3-, 6-, and 12-month survival rates of 94.5%, 73.4%, and 28.5%, respectively. The median survival of stage IV patients was 5.4 months, with 3-, 6-, and 12-month survival rates of 79.3%, 42.9%, and 15.0%, respectively. In multivariate analyses, primary tumor diameter, low albumin, and elevated CA19-9 were associated with decreased survival for stage III patients. Age, smoking, primary tumor diameter, elevated ALT or AST, low albumin, and elevated CA19-9 were associated with decreased survival for stage IV patients.

CONCLUSION

Elevated CA19-9 level, decreased albumin level, and tumor size were associated with worse survival in stage III patients. Meanwhile, advanced age, smoking, and ALT or AST level were negatively correlated to prognosis in stage IV patients.

摘要

目的

我们开展了一项多中心队列研究，以探究一些常用实验室指标在晚期胰腺导管腺癌（PDAC）中的预后价值。

方法

于2004年至2013年进行了一项多中心队列研究。检测了实验室指标与晚期PDAC预后之间的关联。

结果

该队列包括553名女性（36.2%）和973名男性（63.8%）。癌症III期和IV期患者分别为595名（39.0%）和931名（61.0%）。III期患者的中位生存期为9.0个月，3个月、6个月和12个月生存率分别为94.5%、73.4%和28.5%。IV期患者的中位生存期为5.4个月，3个月、6个月和12个月生存率分别为79.3%、42.9%和15.0%。在多因素分析中，原发肿瘤直径、低白蛋白水平和CA19-9升高与III期患者生存率降低相关。年龄、吸烟、原发肿瘤直径、ALT或AST升高、低白蛋白水平和CA19-9升高与IV期患者生存率降低相关。